• Wondering if Qiagen's share price around US$36.59 reflects a fair deal or a mispricing that could matter for your returns? This article walks through what the valuation signals are actually saying.
• Over the very short term, the stock has risen 4.0% over 7 days and 6.8% over 30 days, yet year to date it is still down 23.1% and down 18.6% over the past year, which may catch the eye of investors comparing recent momentum with longer term weakness.
• Recent coverage has focused on Qiagen as a life sciences tools and diagnostics business, with investors watching how its molecular testing and sample preparation products position it in healthcare and research markets. This context helps frame why the stock's recent moves may reflect shifting views on its role in these markets rather than just short term trading noise.
• Qiagen currently scores a 4 out of 6 on its valuation checks, as shown by its valuation score. Next up is a closer look at the different valuation methods behind that score and an even deeper way to think about what the stock might be worth.

Approach 1: Qiagen Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company’s future cash flows and discounts them back to today, aiming to translate those future dollars into a single present value per share.

For Qiagen, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $423.7 million. Analysts provide explicit Free Cash Flow estimates for the next few years, such as $494.5 million in 2026 and $529 million in 2027, and Simply Wall St extrapolates further out, with projected Free Cash Flow of $581 million in 2030 and modestly changing estimates through 2035, all in dollar terms.

When all those projected cash flows are discounted back and combined, the model arrives at an intrinsic value of about $51.34 per share. Compared with the recent share price around $36.59, this implies Qiagen trades at about a 28.7% discount to this DCF estimate, which points to the stock being undervalued on this specific cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Qiagen is undervalued by 28.7%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Qiagen Price vs Earnings

For a profitable company like Qiagen, the P/E ratio is a useful way to gauge what investors are currently willing to pay for each dollar of earnings. It lines up directly with your return expectations on those earnings, so it is a practical cross check against the DCF result you have just seen.

What counts as a “normal” P/E hinges on how quickly earnings are expected to grow and how risky those earnings appear. Higher growth and lower perceived risk usually justify a higher P/E, while lower growth or higher risk tend to pull a fair P/E down.

Qiagen currently trades on a P/E of 18.8x. That sits below the Life Sciences industry average of about 34.3x and well below the peer average of 76.2x, which might initially suggest a cheaper stock. Simply Wall St’s Fair Ratio for Qiagen is 17.6x. This is its view of an appropriate P/E given factors such as earnings growth profile, industry, profit margins, market cap and risk characteristics. This Fair Ratio can be more informative than simple peer or industry comparisons because it adjusts for those company specific features. With the actual P/E only slightly above the Fair Ratio, the stock screens as close to fairly valued on this measure.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Qiagen Narrative

Earlier there was mention that there is an even better way to understand valuation. This is where Narratives come in, giving you a simple story behind the numbers by linking your view on Qiagen’s future revenue, earnings and margins to a forecast and then to a Fair Value that you can compare with today’s price.

On Simply Wall St’s Community page, Narratives are an accessible tool used by millions of investors. You can see and adjust assumptions instead of just staring at a single target, and the Fair Value view then updates as new information such as earnings, guidance or product news comes through.

For Qiagen, one Narrative might assume a Fair Value around US$55.91 based on higher revenue and margin expectations and a 19.5x future P/E. Another might sit closer to US$38.00 with more cautious assumptions and a 17.6x future P/E. This shows you in a practical way how different stories about QuantiFERON, automation platforms and bioinformatics lead to different Fair Values that you can weigh against the current share price.

Do you think there's more to the story for Qiagen? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.